Holding(s) in Company

RNS Number : 8465G
Cizzle Biotechnology Holdings PLC
31 March 2022
 

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATIONOFMAJORHOLDINGS (tobesenttotherelevantissuerandtothe FCAinMicrosoft Word format if possible) i

 

1a.Identityoftheissuerortheunderlyingissuer of existing shares to which voting rights are attached ii :

 

CizzleBiotechnologyHoldingsPlc

1b.Pleaseindicateiftheissuerisanon-UKissuer (pleasemarkwithan"X"ifappropriate)

Non-UKissuer

 

2.Reasonforthenotification (please marktheappropriateboxorboxes withan "X")

Anacquisitionordisposalof votingrights

X

Anacquisition ordisposaloffinancialinstruments

 

Aneventchangingthebreakdownofvotingrights

 

Other(pleasespecify) iii :

 

3.Detailsofpersonsubjecttothenotificationobligation iv

Name

ConduitPharmaceuticalsLimited

Cityandcountryof registeredoffice(if applicable)

GrandCayman

4.Fullnameof shareholder(s) (ifdifferentfrom3.) v

Name

 

Cityandcountryof registeredoffice(if applicable)

 

5.Dateonwhichthethresholdwascrossedor reached vi :

28/02/2022

6.Date onwhichissuernotified(DD/MM/YYYY):

30/03/2022

7.Totalpositions ofperson(s)subjecttothenotificationobligation

 

% of voting rights attachedtoshares (total of 8. A)

%ofvotingrights through financial instruments

(totalof 8.B1+8.B2)

 

Totalofbothin% (8.A + 8.B)

Total number of votingrightsheld

inissuer(8.A+ 8.B) vii

Resulting situation onthedateonwhich threshold was crossed or reached

 

0.00%

 

0.00%

 

0.00%

 

0

Positionofprevious notification (if applicable)

 

8.98%

 

0.00%

 

8.98%

 

             

 

 

8.Notifieddetailsoftheresultingsituationonthedateonwhichthethresholdwascrossedor reached viii

A:Votingrightsattachedtoshares

Class/typeof shares

ISINcode(ifpossible)

Numberofvotingrights ix

%of votingrights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

OrdinaryShares

 

GB00BNG2VN02

 

0

 

0

 

0%

 

0.00%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL8.A

0

0%

 

B1:FinancialInstrumentsaccordingtoDTR5.3.1R(1)(a)

 

Typeoffinancial instrument

 

Expiration date x

 

Exercise/ ConversionPeriod xi

Numberofvotingrights that may be acquired if

the instrument is exercised/converted.

 

%ofvotingrights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL8.B1

 

 

 

B2:FinancialInstruments withsimilareconomiceffectaccordingto DTR5.3.1R(1)(b)

Typeoffinancial instrument

Expiration date x

Exercise/ Conversion Period xi

Physical or cash Settlement xii

Number of votingrights

 

%ofvotingrights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

                   

 

 

9.Informationinrelationtothepersonsubjecttothenotificationobligation (pleasemarkthe applicable box with an "X")

Personsubjecttothenotificationobligation isnotcontrolledbyany naturalperson orlegal entity and doesnot control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

 

Full chainofcontrolledundertakings throughwhichthevotingrightsand/or the

financialinstrumentsareeffectivelyheldstartingwiththe ultimatecontrollingnaturalpersonorlegalentity (please add additional rows as necessary) xiv

 

 

 

Name xv

%ofvotingrightsifit equals or is higher than the notifiable threshold

% of voting rights through financial instrumentsifitequals or is higher than the

notifiablethreshold

Total of both if it equalsorishigher than the notifiable threshold

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. Incase ofproxyvoting,please identify:

Name oftheproxy holder

 

Thenumberand %ofvotingrightsheld

 

Thedateuntilwhich the votingrightswillbe held

 

 

11.Additionalinformation xvi

 

         

 

Placeofcompletion

CaymanIslands

Dateofcompletion

30/03/2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAUNRUNUOOAR
UK 100

Latest directors dealings